Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genelabs/Watson Aslera Lupus Deal Includes $30.5 Mil. In Up-Front Payments

Executive Summary

Watson Pharmaceuticals is investing $30.5 mil. up front to help Genelabs Technologies bring its systemic lupus erythematosus treatment Aslera (prasterone) to market, the companies jointly announced Nov. 13.

You may also be interested in...



Genelabs Requests Meeting With FDA After Aslera "Not-Approvable" Letter

Genelabs plans to meet with FDA to discuss the NDA for its lupus treatment Aslera (prasterone) following receipt of a "not-approvable" letter June 26.

Genelabs Requests Meeting With FDA After Aslera "Not-Approvable" Letter

Genelabs plans to meet with FDA to discuss the NDA for its lupus treatment Aslera (prasterone) following receipt of a "not-approvable" letter June 26.

Watson Moves Reps To Women's, General Divisions For Branded Launches

Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.

Related Content

UsernamePublicRestriction

Register

PS036916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel